select a format

Single User License
USD 250 INR 16030
Site License
USD 500 INR 32060
Corporate User License
USD 750 INR 48090

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH4204D
  • |
  • Pages: 130
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutical ingredients (APIs), infant formulas, and consumer products. The company's major products include analgesics, gastrointestinal, personal care and derma therapeutics, colobetasol spray, clindamycin foam, mupirocin ointment, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drug, supermarket and mass merchandise chains and direct sales representatives. The company has operations in North America, Europe, Australia and other countries including Israel and China. Perrigo is headquartered in Dublin, Ireland.

Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 19

Perrigo Acquires ScarAway Brand from Enaltus 20

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 21

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 22

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 23

Perrigo Acquires OTC Products From Aspen Global For US$51 Million 25

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To US$129 Million 26

Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 27

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 28

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 29

Venture Financing 30

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 30

Proteostasis Therapeutics Raises USD22 Million in Venture Financing 32

Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 32

Proteostasis Therapeutics Raises USD3 Million in Venture Financing 33

Proteostasis Therapeutics Raises US$71 Million In Series A Financing 33

Partnerships 35

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 35

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 36

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 36

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 37

Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 38

Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 43

Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 43

Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 44

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 46

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 46

Oncogenerix Enters into Distribution Agreement with Rosemont Pharma for Soltamox 47

Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 48

Licensing Agreements 49

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 49

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 49

Perrigo Enters into Licensing Agreement with Highland Pharma 50

Perrigo Enters into Licensing Agreement with Flamel Ireland 51

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 52

Perrigo Enters into Licensing Agreement with Imago Pharma 53

Zogenix Amends Agreement with Elan Pharma 53

Perrigo Enters Into Licensing Agreement With Brilite Nutritionals 54

Proteostasis Therapeutics Amends its Licensing Agreement With Harvard University 55

Equity Offering 56

Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 56

Proteostasis Therapeutics Raises USD50 Million in IPO 58

Perrigo Raises USD1.03 Billion in Public Offering of Shares 59

Omega Pharma Completes Public Offering Of Shares For US$237 Million 61

Debt Offering 62

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 63

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 64

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 66

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 67

Perrigo Completes Private Placement Of Notes Due 2023 For US$800 Million 69

Perrigo Completes Private Placement Of Notes Due 2043 For US$400 Million 69

Perrigo Completes Private Placement Of Notes Due 2018 For US$600 Million 70

Perrigo Completes Private Placement Of Notes Due 2016 For US$500 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 72

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 73

Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 74

Perrigo Completes Private Placement Of Notes Due 2023 For US$175 Million 75

Perrigo Completes Private Placement Of Series 2011-A Senior Notes Due 2021 For US$75 Million 76

Perrigo Completes Private Placement Of Series 2011-C Senior Notes Due 2026 For US$100 Million 77

Asset Transactions 77

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 77

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 79

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 80

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 80

Watson Pharma Acquires Generic Pharma Products From Perrigo 81

Acquisition 82

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 82

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 83

Perrigo Acquires Omega Pharma for USD4.76 Billion 84

Ind-Swift Lab May Sell Stake in Company 86

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 87

Perrigo To Acquire 7% Stake In Transition Therapeutics For US$15 Million 87

Perrigo Completes Acquisition Of Elan For US$8.6 Billion 88

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For US$284 Million 91

Omega Pharma Acquires Naturoteek 92

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For US$45 Million 93

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 94

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For US$36 Million 95

Perrigo Completes Acquisition Of Paddock Labs 96

Perrigo Company Plc-Key Competitors 98

Key Employees 99

Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 107

Strategy And Business Planning 107

Jan 11, 2016: Perrigo Company Increases 2016 Full-Year Adjusted Earnings Per Share Guidance 107

Financial Announcements 108

Apr 25, 2017: Perrigo Announces Select Preliminary Unaudited First Quarter 2017 Financial Results 108

Feb 27, 2017: Perrigo Company Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance 109

Nov 10, 2016: Perrigo Company Reports Third Quarter 2016 Financial Results 111

Aug 10, 2016: Perrigo Company Reports Second Quarter 2016 Financial Results 114

May 16, 2016: Perrigo Company Reports First Quarter 2016 Financial Results 116

Feb 18, 2016: Perrigo Company Reports Record Fourth Quarter & Calendar Year Net Sales And Adjusted Net Income 118

Corporate Communications 120

May 08, 2017: Perrigo Announces Two New Independent Directors 120

Feb 27, 2017: Perrigo Announces Leadership Changes 121

Nov 10, 2016: Perrigo Company Announces Appointment of Two New Independent Directors to Board 122

Apr 25, 2016: Perrigo Appoints John T. Hendrickson as Chief Executive Officer, Provides Preliminary First Quarter 2016 Selected Financial Results, and Updates Full Year 2016 Guidance 123

Feb 19, 2016: Perrigo Furthers Commitment to Ireland 124

Product News 125

Apr 12, 2016: Perrigo Announces First-to-Market Launch of the OTC Store Brand Equivalent to Glucerna Aseptic Adult Nutritional Shake 125

Mar 08, 2017: Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine Foam 126

02/17/2017: Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution 127

Other Significant Developments 128

Jan 10, 2017: Perrigo Updates Segment Reporting Structure 128

Dec 08, 2016: Perrigo Announces Portfolio Review Developments And Intention To Restructure Branded Consumer Healthcare's Belgium Business 129

Appendix 130

Methodology 130

About GlobalData 130

Contact Us 130

Disclaimer 130

List of Figures

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

Perrigo Company Plc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Perrigo Company Plc, Deals By Therapy Area, 2011 to YTD 2017 11

Perrigo Company Plc, Medical Devices Deals, 2011 to YTD 2017 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 19

Perrigo Acquires ScarAway Brand from Enaltus 20

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 21

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 22

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 23

Perrigo Acquires OTC Products From Aspen Global For US$51 Million 25

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To US$129 Million 26

Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 27

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 28

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 29

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 30

Proteostasis Therapeutics Raises USD22 Million in Venture Financing 32

Proteostasis Therapeutics Raises Additional USD2 Million in Venture Financing 32

Proteostasis Therapeutics Raises USD3 Million in Venture Financing 33

Proteostasis Therapeutics Raises US$71 Million In Series A Financing 33

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 35

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 36

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 36

Proteostasis Therapeutics Amends Research Agreement with Astellas Pharma 37

Proteostasis Therapeutics Extends Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 38

Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 43

Proteostasis Therapeutics Enters Into Co-Development Agreement With Scripps Research Institute 43

Proteostasis Therapeutics Enters into Co-Development Agreement with Cystic Fibrosis Foundation Therapeutics 44

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 46

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 46

Oncogenerix Enters into Distribution Agreement with Rosemont Pharma for Soltamox 47

Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 48

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 49

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 49

Perrigo Enters into Licensing Agreement with Highland Pharma 50

Perrigo Enters into Licensing Agreement with Flamel Ireland 51

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 52

Perrigo Enters into Licensing Agreement with Imago Pharma 53

Zogenix Amends Agreement with Elan Pharma 53

Perrigo Enters Into Licensing Agreement With Brilite Nutritionals 54

Proteostasis Therapeutics Amends its Licensing Agreement With Harvard University 55

Proteostasis Therapeutics Raises USD65 Million in Public Offering of Shares 56

Proteostasis Therapeutics Raises USD50 Million in IPO 58

Perrigo Raises USD1.03 Billion in Public Offering of Shares 59

Omega Pharma Completes Public Offering Of Shares For US$237 Million 61

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 63

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 64

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 66

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 67

Perrigo Completes Private Placement Of Notes Due 2023 For US$800 Million 69

Perrigo Completes Private Placement Of Notes Due 2043 For US$400 Million 69

Perrigo Completes Private Placement Of Notes Due 2018 For US$600 Million 70

Perrigo Completes Private Placement Of Notes Due 2016 For US$500 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 72

Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 73

Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 74

Perrigo Completes Private Placement Of Notes Due 2023 For US$175 Million 75

Perrigo Completes Private Placement Of Series 2011-A Senior Notes Due 2021 For US$75 Million 76

Perrigo Completes Private Placement Of Series 2011-C Senior Notes Due 2026 For US$100 Million 77

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 77

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 79

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 80

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 80

Watson Pharma Acquires Generic Pharma Products From Perrigo 81

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 82

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 83

Perrigo Acquires Omega Pharma for USD4.76 Billion 84

Ind-Swift Lab May Sell Stake in Company 86

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 87

Perrigo To Acquire 7% Stake In Transition Therapeutics For US$15 Million 87

Perrigo Completes Acquisition Of Elan For US$8.6 Billion 88

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For US$284 Million 91

Omega Pharma Acquires Naturoteek 92

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For US$45 Million 93

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 94

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For US$36 Million 95

Perrigo Completes Acquisition Of Paddock Labs 96

Perrigo Company Plc, Key Competitors 98

Perrigo Company Plc, Key Employees 99

Perrigo Company Plc, Subsidiaries 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Perrigo Company Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com